Comment
doi: 10.1056/NEJMc1806646.
Edoxaban for Cancer-Associated Venous Thromboembolism
Affiliations
- PMID: 29975029
- DOI: 10.1056/NEJMc1806646
Item in Clipboard
Comment
Edoxaban for Cancer-Associated Venous Thromboembolism
N Engl J Med.
.
Free article
No abstract available
Comment in
-
Edoxaban for Cancer-Associated Venous Thromboembolism.N Engl J Med. 2018 Jul 5;379(1):95-96. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29972743 No abstract available.
Comment on
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231094 Clinical Trial.
Similar articles
-
Edoxaban for Cancer-Associated Venous Thromboembolism.N Engl J Med. 2018 Jul 5;379(1):94-5. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975033 No abstract available.
-
Edoxaban for Cancer-Associated Venous Thromboembolism.N Engl J Med. 2018 Jul 5;379(1):94. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975032 No abstract available.
-
Edoxaban for Cancer-Associated Venous Thromboembolism.N Engl J Med. 2018 Jul 5;379(1):93-4. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975031 No abstract available.
-
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism.BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29. BMJ Evid Based Med. 2018. PMID: 29959155 Review. No abstract available.
-
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.Cardiol Rev. 2016 Jul-Aug;24(4):205-10. doi: 10.1097/CRD.0000000000000104. Cardiol Rev. 2016. PMID: 26991962 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
